Answers are grounded in this paper and cite their sources.
Although a pathogenic role for the Epstein-Barr virus (EBV) is largely undisputed for tumors that are consistently EBV genome positive (eg, nasopharyngeal carcinoma, endemic Burkitt lymphoma), this is not the case for classical Hodgkin lymphoma (cHL), a tumor with only a variable EBV association. In light of recent developments in immunotherapeutics and small molecules targeting EBV, we believe it is now timely to reevaluate the role of EBV in cHL pathogenesis.
No takes yet. Share an insight, caveat, or question.
Murray et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: